pyrroles has been researched along with Carcinoma, Transitional Cell in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 5 (23.81) | 2.80 |
| Authors | Studies |
|---|---|
| Breitbach, JT; Fenger, JM; Geisler, JA; Husbands, BD; Korec, DI; Louke, DS | 1 |
| Féliz, L; Gutierrez, M; Iannotti, NO; Ji, T; Lihou, CF; Saleh, M; Silverman, IM; Smith, DC; Subbiah, V; Tian, C | 1 |
| Bian, XJ; Cai, J; Chen, C; Han, W; He, C; Luo, H; Qu, YY; Sun, Z; Wang, Q; Xing, N; Ye, DW; Zhang, X; Zou, Q | 1 |
| Bender, S; Boix, O; Cassier, PA; Cathomas, R; Cho, BC; Ellinghaus, P; Gajate, P; Grevel, J; Joerger, M; Navarro, A; Nogai, H; Nogova, L; Ocker, M; Park, SH; Penel, N; Rajagopalan, P; Richly, H; Sayehli, CM; Schostak, M; Schuler, M; Soo, RA; Tai, D | 1 |
| Bossaer, JB; Weaver, A | 1 |
| Hubert, P; Loriot, Y; Selmani, Z; Thiery-Vuillemin, A | 1 |
| Amantini, C; Berardi, R; Bonfili, L; Burattini, L; Cascinu, S; Eleuteri, AM; Farfariello, V; Liberati, S; Morelli, MB; Mozzicafreddo, M; Nabissi, M; Santoni, G; Santoni, M | 1 |
| Al-Hawary, M; Bylow, KA; Daignault, S; Dreicer, R; Grivas, PD; Hussain, M; Keller, ET; Kohli, M; Nanus, DM; Petrylak, DP; Smith, DC; Sottnik, JL; Stadler, WM; Tagawa, ST; Vaughn, DJ; Wong, SG | 1 |
| Ji, ZG; Jin, J; Li, HZ; Wen, J | 1 |
| Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
| Chew, DJ; Drost, WT; Gardner, HL; Green, EM; Hostnik, ET; London, CA; Nguyen, SM; Peng, J; Portela, RA; Rippy, SB; Warry, EE | 1 |
| Hes, O; Mardiak, J; Mego, M; Obertova, J; Rajec, J; Rejlekova, K; Rychly, B; Sycova-Mila, Z | 1 |
| Ping, SY; Wu, CL; Yu, DS | 1 |
| Bellmunt, J; Choueiri, TK; Katz, L | 1 |
| Chester, JD; Cooper, PA; Knowles, MA; Lamont, FR; Shnyder, SD; Tomlinson, DC | 1 |
| Aguilar, G; Albanell, J; Bellmunt, J; Calvo, A; Carles, J; Castellano, D; Gallardo, E; González-Larriba, JL; Maroto, P; Mellado, B; Perez-Gracia, JL; Prior, C; Villanueva, X | 1 |
| Al-Ahmadie, H; Bajorin, DF; Flaherty, AM; Gallagher, DJ; Garcia-Grossman, I; Gerst, SR; Gounder, SK; Milowsky, MI; Ostrovnaya, I; Regazzi, A; Riches, J; Trout, A | 1 |
| Alandas, MN; Cooper, PA; Gill, JH; Illingworth, NA; Laye, JP; Loadman, PM; Patterson, LH; Pors, K; Searcey, M; Sheldrake, HM; Shnyder, SD; Sutherland, M | 1 |
| Asmar, L; Galsky, MD; Gardner, TA; Hahn, NM; Hellerstedt, BA; Hutson, TE; Kocs, D; Lerner, SP; McKenney, SA; Melnyk, AM; O'Rourke, M; Powles, T; Rauch, M; Sonpavde, G; Vogelzang, NJ; Wang, Y; Yu, M | 1 |
| Vogelzang, NJ | 1 |
| Kamat, AM; Nelkin, GM | 1 |
2 review(s) available for pyrroles and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
Topics: Bile Duct Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Clinical Trials as Topic; Humans; Morpholines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3 | 2021 |
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
6 trial(s) available for pyrroles and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Cholangiocarcinoma; Female; Fibroblast Growth Factors; Humans; Lung Neoplasms; Male; Morpholines; Neoplasm Recurrence, Local; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Fibroblast Growth Factor; Urinary Bladder Neoplasms | 2022 |
Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Humans; Indoles; Male; Platinum; Pyrroles; Urinary Bladder Neoplasms | 2022 |
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Topics: Acute Kidney Injury; Aged; Anorexia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Diarrhea; Fatigue; Female; Humans; Hyperphosphatemia; Hypoglycemia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Fibroblast Growth Factor; RNA, Messenger; Squamous Cell Carcinoma of Head and Neck; Thiophenes; Vomiting | 2019 |
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Transitional Cell; Confounding Factors, Epidemiologic; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Pyrroles; Sample Size; Sunitinib; Treatment Outcome; Urologic Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cisplatin; Contrast Media; Disease-Free Survival; Female; Humans; Indoles; Interleukin-8; Kaplan-Meier Estimate; Male; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Urologic Neoplasms | 2011 |
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pyrroles; Sunitinib; Survival Rate; Urinary Bladder Neoplasms; Urothelium | 2013 |
13 other study(ies) available for pyrroles and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines.
Topics: Animals; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Dog Diseases; Dogs; Female; Indoles; Male; Pyrroles; Receptor Protein-Tyrosine Kinases; Urinary Bladder Neoplasms | 2021 |
FGFR alterations in urothelial carcinoma: Picking the right target.
Topics: Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Gene Fusion; Humans; Molecular Targeted Therapy; Morpholines; Mutation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Thiophenes; Urinary Bladder Neoplasms | 2021 |
Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Death; Cell Line, Tumor; Cell Survival; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Membrane Potential, Mitochondrial; Necrosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reactive Oxygen Species; Sulfonamides; Sunitinib; Urinary Bladder Neoplasms | 2013 |
Effects of sunitinib malate on growth of human bladder transitional cell line T24 in vitro.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Fas Ligand Protein; fas Receptor; Humans; In Vitro Techniques; Indoles; Poly(ADP-ribose) Polymerases; Pyrroles; Sunitinib; Urinary Bladder Neoplasms; Wound Healing | 2015 |
A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Dog Diseases; Dogs; Female; Indoles; Male; Pilot Projects; Pyrroles; Reproducibility of Results; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Sunitinib in the treatment of tubulocystic carcinoma of the kidney. A case report.
Topics: Adult; Biopsy, Needle; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Diagnosis, Differential; Drug Administration Schedule; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Neoplasm Staging; Nephrectomy; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; BCG Vaccine; Bcl-2-Like Protein 11; bcl-X Protein; Blotting, Western; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Membrane Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2012 |
¹¹C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Neoplasms; Carbon Radioisotopes; Carcinoma, Transitional Cell; Humans; Indoles; Methionine; Positron-Emission Tomography; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
Topics: Animals; Apoptosis; Benzimidazoles; Blotting, Western; Carcinoma, Transitional Cell; Cell Cycle; Cell Proliferation; Cells, Cultured; Humans; Immunoenzyme Techniques; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; Mutation; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 3; Urinary Bladder Neoplasms; Urothelium; Xenograft Model Antitumor Assays | 2011 |
Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response.
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Pressure; Carcinoma, Transitional Cell; Cell Cycle Proteins; Drug Administration Schedule; Humans; Hypertension; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Logistic Models; New York City; Phosphoproteins; Phosphorylation; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Tissue Array Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Urologic Neoplasms; Urothelium; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.
Topics: Animals; Antineoplastic Agents; Biotransformation; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetinae; Cytochrome P-450 CYP1A1; Female; Gene Expression; Humans; Indoles; Liver; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Microsomes, Liver; Pyrroles; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma.
Topics: Acute Disease; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Male; Neoplasm Metastasis; Neutropenia; Pancreatitis; Pyrroles; Sunitinib; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2013 |
Atorvastatin: a potential chemopreventive agent in bladder cancer.
Topics: Atorvastatin; Carcinoma, Transitional Cell; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Urinary Bladder Neoplasms | 2005 |